How Waters Beats The Cycle
32:08–32:56 · 48s
Batra attributes outperformance to downstream regulated niches and software embedded in 80% of new drug filings, citing broad pharma growth globally.
32:08–32:56 · 48s
Batra attributes outperformance to downstream regulated niches and software embedded in 80% of new drug filings, citing broad pharma growth globally.
We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.